Novadip Biosciences has raised $11.9M in Series B funding to advance its regenerative tissue products for large bone defects and injuries.
The Belgian clinical-stage biopharmaceutical company is developing NVD-X3, an off-the-shelf allogeneic product designed to accelerate tissue healing and ship at room temperature, and NVD-003, an autologous therapy for congenital pseudarthrosis of the tibia, a rare pediatric bone condition. The round drew backing from New Science Ventures, Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq, and invest.bw.
.png&w=3840&q=75)
